An innovation for adults that delivers 4 oils in 1 lipid emulsion
Supply of monounsaturated fatty acids
Mix of fatty acids
Omega-3 fatty acids from fish oil include EPA and DHA
First and only 4-oil lipid emulsion for adult and pediatric patients, including term and preterm neonates1
SMOFlipid is the FIRST and ONLY 4-oil lipid injectable emulsion with a well-established safety and tolerability profile.1 It has been administered to more than 7 million patients worldwide.*
*Data on file 12/1/23.
Discover the SMOF Difference
-
Soybean oil 30%
(omega-6) Provides essential fatty acids.
-
Medium-chain triglycerides (MCT) 30%
A source of rapidly available energy.2
-
Olive oil 25%
(omega-9) Supplies monounsaturated fatty acids.
-
Fish oil 15%
(omega-3) A source of EPA and DHA.3
Characteristics of the blend
Each oil has characteristics which provide a unique blend. In one clinical study:
Parameters of Liver Function at Baseline and at Week 4
This randomized, double-blind, multi-center study compared PN containing SMOFlipid or a soybean oil emulsion in intestinal failure patients requiring long-term PN.4 Seventy-three patients (n = 34 in SMOFlipid group and n = 39 in the soybean oil group) received PN with either lipid emulsion and were monitored for 4 weeks.4
PN intake was similar in both groups: 1.3 g/kg/d ILE, 3 g/kg/d dextrose, 1.2 g/kg/d amino acids.4 Infusion occurred 10-24 hr/d, 5-7 days per week.4
After 4 weeks, the mean concentrations of ALT, AST, and total bilirubin were significantly lower in the SMOFlipid group than the comparator group (statistical significance was set at P < 0.05).4
Monitor liver function. If SMOFlipid-treated patients develop liver enzyme abnormalities, consider discontinuation or dose reduction.
Indication
SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.1
KabiCare Patient Support Program for Parenteral Nutrition
Fresenius Kabi’s patient support program, KabiCare, offers online resources for claims appeals and billing as well as coding guides for parenteral nutrition.
SMOFlipid resources
Explore additional SMOFlipid materials by visiting our Resource Center.
For Consumers
SMOFLIPID® (lipid injectable emulsion USP), for intravenous use
IMPORTANT SAFETY INFORMATION
What is SMOFlipid?
- Indicated in adult and pediatric patients as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated.
- The hourly infusion rate in pediatrics should not exceed 0.75 mL/kg/hour and 0.5 mL/kg/hour in adults.
SMOFlipid should not be received by patients who have:
- A known allergy to fish, egg, soybean, or peanut, or to any of the active or inactive ingredients in SMOFlipid.
- Abnormally high levels of lipid (triglycerides) in the blood.
SMOFlipid may cause serious side effects including:
- Serious Adverse Reactions with Rapid Infusion of Intravenous Lipid Emulsion in Neonates and Infants: Strictly follow the recommended total daily dosage and do not exceed the maximum infusion rate. If poor clearance of fats occurs, the infusion should be stopped, and a medical evaluation started.
- Risk of Parenteral Nutrition-Associated Liver Disease: Parenteral nutrition-associated liver disease (PNALD) may progress to liver inflammation and damage caused by a buildup of fat in the liver with scarring and cirrhosis.
- Allergic Reactions: Contact your healthcare provider immediately if you are experiencing an allergic reaction.
- Fat Overload Syndrome, Refeeding Syndrome, Elevated Triglycerides (Hypertriglyceridemia): Your healthcare provider will monitor you for signs and symptoms of early infection and blood levels.
Monitoring/Laboratory Tests: The content of vitamin K may interfere with blood clotting activity of medications.
For Consumers
SMOFLIPID® (lipid injectable emulsion USP), for intravenous use
IMPORTANT SAFETY INFORMATION
What is SMOFlipid?
- Indicated in adult and pediatric patients as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated.
- The hourly infusion rate in pediatrics should not exceed 0.75 mL/kg/hour and 0.5 mL/kg/hour in adults.
SMOFlipid should not be received by patients who have:
- A known allergy to fish, egg, soybean, or peanut, or to any of the active or inactive ingredients in SMOFlipid.
- Abnormally high levels of lipid (triglycerides) in the blood.
SMOFlipid may cause serious side effects including:
- Serious Adverse Reactions with Rapid Infusion of Intravenous Lipid Emulsion in Neonates and Infants: Strictly follow the recommended total daily dosage and do not exceed the maximum infusion rate. If poor clearance of fats occurs, the infusion should be stopped, and a medical evaluation started.
- Risk of Parenteral Nutrition-Associated Liver Disease: Parenteral nutrition-associated liver disease (PNALD) may progress to liver inflammation and damage caused by a buildup of fat in the liver with scarring and cirrhosis.
- Allergic Reactions: Contact your healthcare provider immediately if you are experiencing an allergic reaction.
- Fat Overload Syndrome, Refeeding Syndrome, Elevated Triglycerides (Hypertriglyceridemia): Your healthcare provider will monitor you for signs and symptoms of early infection and blood levels.
Monitoring/Laboratory Tests: The content of vitamin K may interfere with blood clotting activity of medications.